Tumor Immunology in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is characterised by a profoundly immunosuppressive microenvironment in which malignant cells exploit both stromal and immune components to evade destruction. Oncogenic mutations drive secretion of cytokines and chemokines that recruit regulatory T cells, myeloid-derived suppressor cells and tumour-associated macrophages, while cancer-associated fibroblasts and a dense extracellular matrix impose a physical barrier to effector lymphocytes. Recent studies have also implicated the tumour-associated microbiome in shaping immune cell infiltration and checkpoint ligand dynamics. A low mutational burden and deficient antigen presentation further limit cytotoxic T-cell responses, contributing to weak immunogenicity. Consequently, single-agent immune checkpoint inhibitors have yielded modest clinical benefit. Advances in understanding the interplay between neoplastic, stromal and immune elements have prompted combination strategies, including CD40 agonists, vaccines, adoptive cell therapies and metabolic reprogramming of the microenvironment. These approaches seek to convert PDAC from an immune-excluded to an immune-inflamed state, with the ultimate aim of enhancing tumour clearance and improving patient survival on a global scale.

Research from Nature Portfolio

Two seminal articles illustrate the evolving landscape of immuno-modulation in PDAC. A randomised phase II trial combining gemcitabine–nab-paclitaxel with anti-PD-1 and CD40 agonist antibodies met its primary endpoint for 1-year overall survival, revealing that patients responding to PD-1 blockade exhibited a less suppressive myeloid milieu and an abundance of activated, antigen-experienced T cells. In parallel, a computational imaging study demonstrated that the spatial proximity of cytotoxic CD8+ T cells to neoplastic cells correlates strongly with patient survival, challenging the notion that desmoplasia acts solely as a physical barrier. Together, these findings underscore the necessity of both systemic immune modulation and precise orchestration of effector cell localisation for successful immunotherapy in PDAC.

Tumor Immunology in Pancreatic Cancer publication trend

The graph below shows the total number of articles in tumor immunology in pancreatic cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Tumour microenvironment: The complex milieu of cancer cells, stromal elements, immune cells and extracellular matrix that influences tumour growth and immune evasion.

Immune checkpoint: A regulatory pathway, such as PD-1/PD-L1 or CTLA-4, that modulates T-cell activation and maintains self-tolerance but may be exploited by tumours.

Regulatory T cell (Treg): A subset of CD4+ T cells that suppresses immune responses and contributes to tumour-induced tolerance.

Myeloid-derived suppressor cell (MDSC): An immature myeloid population that inhibits T-cell function and promotes tumour progression.

Cancer-associated fibroblast (CAF): A stromal cell type that produces extracellular matrix components and immunosuppressive factors within the tumour niche.

Neoantigen: A novel peptide arising from tumour-specific mutations that can be recognised by the immune system but may be under-presented in PDAC.

References

1. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Molecular Cancer (2023).
2. Current and future immunotherapeutic approaches in pancreatic cancer treatment. Journal of Hematology & Oncology (2024).
3. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nature Communications (2017).
4. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine (2022).